Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA) has received a consensus rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.43.

Several research analysts recently commented on the company. Craig Hallum downgraded Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $7.00 to $5.00 in a research note on Friday, November 15th. Canaccord Genuity Group cut Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th.

Akoya Biosciences Stock Down 3.9 %

NASDAQ AKYA opened at $2.96 on Friday. The business has a fifty day moving average price of $2.50 and a 200 day moving average price of $2.60. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75. The company has a market cap of $146.73 million, a P/E ratio of -2.51 and a beta of 1.18.

Hedge Funds Weigh In On Akoya Biosciences

A number of hedge funds have recently modified their holdings of AKYA. SG Americas Securities LLC purchased a new position in shares of Akoya Biosciences during the 4th quarter worth $28,000. Regal Investment Advisors LLC grew its holdings in shares of Akoya Biosciences by 64.3% during the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after purchasing an additional 7,340 shares during the period. Barclays PLC grew its holdings in shares of Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after purchasing an additional 30,095 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Akoya Biosciences by 16.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock worth $158,000 after purchasing an additional 9,429 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in shares of Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after purchasing an additional 144,903 shares during the period. 79.42% of the stock is currently owned by hedge funds and other institutional investors.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.